Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study

Ru Dee Ting*, Anthony C. Keech, Paul L. Drury, Mark W. Donoghoe, John Hedley, Alicia J. Jenkins, Timothy M E Davis, Seppo Lehto, David Celermajer, R. John Simes, Kushwin Rajamani, Kim Stanton

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

84 Citations (Scopus)

Abstract

OBJECTIVE - Diabetic patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30-59 mL/min/1.73 m 2) are at particular cardiovascular risk. Fenofibrate's safety in these patients is an issue because it may elevate plasma creatinine. Furthermore, guidelines regarding fenofibrate dosing in renal impairment vary internationally. We investigated fenofibrate's effects on cardiovascular and end-stage renal disease (ESRD) events, according to eGFR, in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. RESEARCH DESIGN AND METHODS - Type 2 diabetic patients (aged 50-75 years) with eGFR>30 mL/min/1.73 m 2 were randomly allocated to a fixed dose of fenofibrate (200 mg daily) (n = 4,895) or placebo (n = 4,900) for 5 years. Baseline renal function (Modification of Diet in Renal Disease equation) was grouped by eGFR (30-59, 60-89, and ≥90 mL/min/1.73 m 2). The prespecified outcome was total cardiovascular events (composite of cardiovascular death, myocardial infarction, stroke, and coronary/carotid revascularization). Serious adverse events and instances of ESRD (plasma creatinine >400 μmol/L, dialysis, renal transplant, or renal death) were recorded. Analysis was by intention to treat. RESULTS - Overall, fenofibrate reduced total cardiovascular events, compared with placebo (hazard ratio 0.89 [95% CI 0.80-0.99]; P = 0.035). This benefit was not statistically different across eGFR groupings (P = 0.2 for interaction) (eGFR 30-59 mL/min/1.73 m 2: 0.68 [0.47-0.97], P = 0.035; eGFR ≥90 mL/min/1.73 m 2: 0.85 [0.70-1.02], P = 0.08). ESRD rates were similar between treatment arms, without adverse safety signals of fenofibrate use in renal impairment. CONCLUSIONS - Patients with type 2 diabetes andmoderate renal impairment benefit from long-term fenofibrate, without excess drug-related safety concerns compared with those with no ormild renal impairment. Fenofibrate treatment should not be contraindicated in moderate renal impairment, suggesting that current guidelines may be too restrictive.

Original languageEnglish
Pages (from-to)218-225
Number of pages8
JournalDiabetes Care
Volume35
Issue number2
DOIs
Publication statusPublished - Feb 2012
Externally publishedYes

Fingerprint

Dive into the research topics of 'Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study'. Together they form a unique fingerprint.

Cite this